Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 13/20 | 0.46 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7922412 | 0.99 | GRM2 (0.47) | GRM2TLR8 | |
| SCHEMBL7923909 | 0.99 | GRM2 (0.47) | GRM2TLR8 | |
| SCHEMBL2219269 | 0.99 | GRM2 (0.47) | GRM2TLR8 | |
| SCHEMBL2221015 | 0.86 | HPGD (0.37) | GRM2NPC1POLBMAPTRAB9A | |
| SCHEMBL2220577 | 0.86 | GRM2 (0.36) | GRM2NPC1MAPTRAB9A | |
| SCHEMBL12441184 | 0.86 | ALDH1A1 (0.36) | GRM2NPC1MAPTRAB9A | |
| SCHEMBL12597541 | 0.85 | USP2 (0.41) | NPC1POLBMAPTRAB9A | |
| SCHEMBL7925050 | 0.85 | HPGD (0.38) | GRM2NPC1POLBMAPTRAB9A | |
| SCHEMBL2220997 | 0.84 | KDM4E (0.35) | TLR8POLBMAPTRAB9A | |
| SCHEMBL2221116 | 0.83 | PTAFR (0.41) | GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178117-A1 | OXAZOLOBENZIMIDAZOLE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110178117-A1 | OXAZOLOBENZIMIDAZOLE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2011-07-21 | — | — | US | disclosed |
| WO-2010036544-A1 | OXAZOLOBENZIMIDAZOLE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178117-A1 | OXAZOLOBENZIMIDAZOLE DERIVATIVES | GRM2, GRM1, GRM3 | GRM2 1/4885TLR8 697/4885NPC1 2542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.